Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 6/20 | 0.52 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.52 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.52 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.52 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.52 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2536306 | 1.00 | CHRNB2 (0.52) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| SCHEMBL2531727 | 1.00 | CHRNB2 (0.52) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| SCHEMBL13685207 | 1.00 | CHRNB2 (0.52) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| SCHEMBL2536298 | 1.00 | CHRNB2 (0.52) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| SCHEMBL13684818 | 1.00 | CHRNB2 (0.52) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| SCHEMBL2534652 | 0.98 | CHRNB2 (0.54) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| SCHEMBL2540236 | 0.91 | CHRNB2 (0.56) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| SCHEMBL8372848 | 0.89 | CHRNB2 (0.62) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| SCHEMBL1890522 | 0.82 | — | — | |
| SCHEMBL25277070 | 0.81 | NAAA (0.57) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120302782-A1 | PROCESS FOR PREPARING A CARBAMATE COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2012-11-29 | — | — | US | disclosed |
| EP-2522736-A1 | PROCESS FOR PRODUCTION OF CARBAMATE COMPOUND | Ube Industries, Ltd. (JP) | 2012-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302782-A1 | PROCESS FOR PREPARING A CARBAMATE COMPOUND | ALKBH3, DNPH1, NCEH1 | CHRNB2 3075/4885CHRNA4 1866/4885CHRM2 2232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.